4D pharma plc (LBPS): Price and Financial Metrics
GET POWR RATINGS... FREE!
LBPS Stock Summary
- Of note is the ratio of 4D Pharma PLC's sales and general administrative expense to its total operating expenses; merely 3.24% of US stocks have a lower such ratio.
- LBPS's price/sales ratio is 1,722.55; that's higher than the P/S ratio of 99.74% of US stocks.
- Revenue growth over the past 12 months for 4D Pharma PLC comes in at -28.99%, a number that bests only 5.67% of the US stocks we're tracking.
- Stocks that are quantitatively similar to LBPS, based on their financial statements, market capitalization, and price volatility, are WIMI, ENVB, XM, DNMR, and CNET.
- To dig deeper into the stock's financial statements, go to LBPS's page on browse-edgar?action=getcompany&CIK=0001830162.
LBPS Valuation Summary
- In comparison to the median Healthcare stock, LBPS's EV/EBIT ratio is 241.64% lower, now standing at -41.5.
- LBPS's price/sales ratio has moved NA NA over the prior 37 months.
- Over the past 37 months, LBPS's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for LBPS.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| LBPS | 2021-08-31 | 1852.3 | 32.8 | -41.9 | -41.5 |
| LBPS | 2021-08-30 | 1910.1 | 33.8 | -43.2 | -42.8 |
| LBPS | 2021-08-27 | 1888.1 | 33.4 | -42.7 | -42.3 |
| LBPS | 2021-08-26 | 1924.3 | 34.1 | -43.5 | -43.2 |
| LBPS | 2021-08-25 | 1865.4 | 33.0 | -42.2 | -41.8 |
| LBPS | 2021-08-24 | 1730.0 | 30.6 | -39.1 | -38.8 |
LBPS Stock Price Chart Interactive Chart >
LBPS Price/Volume Stats
| Current price | $3.36 | 52-week high | $12.47 |
| Prev. close | $3.13 | 52-week low | $2.74 |
| Day low | $3.26 | Volume | 77,100 |
| Day high | $3.66 | Avg. volume | 278,202 |
| 50-day MA | $4.09 | Dividend yield | N/A |
| 200-day MA | $5.87 | Market Cap | 55.21M |
4D pharma plc (LBPS) Company Bio
4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company's development programs include Blautix for irritable bowel syndrome and Thetanix for paediatric crohn's disease. It also develops immuno-oncology products comprising MRx0518, MRx0573, and MRx1299 for solid tumors, and MRx0518 for pancreatic cancer; respiratory products, such as MRx-4DP0004 for asthma and COVID-19; central nervous system products, including MRx0005 and MRx0029 for neurodegeneration; and platform products comprising vaccines and autoimmune. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumours. The company was formerly known as Schosween 18 Limited. 4D pharma plc was founded in 2014 and is headquartered in Leeds, the United Kingdom.
Latest LBPS News From Around the Web
Below are the latest news stories about 4D Pharma PLC that investors may wish to consider to help them evaluate LBPS as an investment opportunity.
4D pharma to Participate at the Chardan Metagenomics and Microbiome Medicines SummitLEEDS, England, February 23, 2022--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announced that Duncan Peyton, Chief Executive Officer, and Alex Stevenson, Chief Scientific Officer of 4D pharma, will participate in a fireside chat at the Chardan Metagenomics and Microbiome Medicines Summit on Tuesday, March 1, 2022 at 9:00 a.m. ET (2:00 p.m. GMT). |
4D Pharma To Test Its Single-Strain Live Biotherapeutics In Parkinson's DiseaseThe FDA has signed off 4D pharma plc's (NASDAQ: LBPS) investigational new drug (IND) applications for two Live Biotherapeutics (LBPs), MRx0005 and MRx0029, for Parkinson's disease. The Company expects to initiate a first-in-human Phase I clinical trial in people with Parkinson's disease in mid-2022. "We believe MRx0005 and MRx0029 are the first ever Live Biotherapeutic products for Parkinson's to enter the clinic," said Dr. Alex Stevenson, Chief Scientific Officer, 4D pharma. "Current treatments |
4D pharma Announces FDA Clearance of IND Application for Live Biotherapeutics MRx0005 and MRx0029 for the Treatment of Parkinson’s DiseaseLEEDS, England, February 22, 2022--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that the U.S. Food and Drug Administration (FDA) has cleared investigational new drug (IND) applications for two Live Biotherapeutics (LBPs), MRx0005 and MRx0029, for the treatment of Parkinson’s disease. The Company expects to initiate a first-in-human Phase I clinic |
4D Pharma restates first-half earnings due to accounting changeThe London- and U.S.-listed pharmaceutical company said the warrants and units should be recorded as derivative liabilities and not equity instruments under both IFRS and U.S. GAAP accounting standards. |
Ladenburg Thalmann & Co. Thinks 4d Pharma’s Stock is Going to RecoverLadenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on 4d Pharma (LBPS – Research Report) today and set a price target of $35.00. The company's shares closed last Thursday at $4.03, close to its 52-week low of $3.55. According to TipRanks.com, Higgins is a 3-star analyst with an average return of 3.5% and a 29.8% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Zynerba Pharmaceuticals, and Armata Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for 4d Pharma with a $35.00 average price target. |
LBPS Price Returns
| 1-mo | N/A |
| 3-mo | -12.27% |
| 6-mo | -58.05% |
| 1-year | -68.00% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -38.35% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...